window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-4PR1PSYQLJ'); Skip to content

Welcome to Discover Pharma! Today is : May 6, 2026

  • News
  • Featured News Archives
    • 12 Days of Christmas
    • Women in Pharma
  • About Us
Contact Us

Biotech & Pharma Business

  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development,Therapeutic Areas

    Evogene partners QUT on AI drug discovery for lung cancer resistance

    Evogene Ltd has partnered with Queensland University of Technology to [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Pharmaceuticals and therapeutics,Therapeutic Areas

    Sensei acquires Faeth and secures $200M to advance PIKTOR in endometrial and breast cancer

    Sensei Biotherapeutics has acquired Faeth Therapeutics and announced a concurrent [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Discovery & Development,Therapeutic Areas

    Axol Bioscience acquires Newcells ophthalmology business to expand retinal organoid portfolio

    Axol Bioscience has acquired the ophthalmology business of Newcells Biotech, [...]

    May 5, 2026
  • Biotech & Pharma Business,Drug Delivery & Formulation,Manufacturing & Supply Chain,Pharmaceuticals and therapeutics

    Axplora expands lyophilisation capacity at Le Mans

    Axplora is investing several million euros to expand lyophilisation capacity [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Pharmaceuticals and therapeutics,Therapeutic Areas

    Polaryx therapeutics selects contract research organization for SOTERIA phase 2 basket trial

    Polaryx Therapeutics, Inc has selected a leading contract research organization [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Digital & Data,Drug Discovery & Development,Pharmaceuticals and therapeutics

    AI and medical affairs strategy set to redefine life sciences in 2026

    Artificial intelligence, shifting healthcare professional behaviour and rising pressure on [...]

    May 5, 2026
  • Biotech & Pharma Business,Digital & Data,Drug Discovery & Development

    Nuclera and leadXpro partner on AI-guided workflow for membrane protein drug discovery

    Nuclera and leadXpro have entered a scientific partnership to develop [...]

    May 5, 2026
  • Biotech & Pharma Business,Clinical & Regulatory,Drug Discovery & Development,Therapeutic Areas

    FundaMental Pharma to present FMP374 preclinical data in treatment-resistant depression at Bio-Neuroscience Conference

    FundaMental Pharma GmbH will present new preclinical data on its [...]

    May 5, 2026
  • Biotech & Pharma Business,Medical devices,Therapeutic Areas

    Neupulse secures £3M to advance neurotherapeutic device for Tourette Syndrome

    Neupulse, a UK-based neurotherapeutics company, has raised £3 million in [...]

    May 5, 2026
  • Biotech & Pharma Business,Central Nervous System,Clinical & Regulatory

    Newron secures up to EUR 38 million to advance Phase 3 evenamide program in treatment-resistant schizophrenia

    Newron Pharmaceuticals has secured up to EUR 38 million in [...]

    May 5, 2026
Previous678Next

Bringing you the latest industry news and insights every day

Registered Address: Discover Pharma Ltd, 1 Dartmouth Close, Brighton, BN2 4HZ, UK
Company Number: 16239596

  • About Us
  • Contact Us
  • Legal
    • Cookie Policy
    • Privacy Policy
    • Terms & Conditions
  • Author Guidelines
    • Pharmaceutical Author Guidelines
    • Press Release Advice
  • Advertise with Us
  • Media Kit Request

© 2026 Discover Pharma. All rights reserved • Developed by Hairy Goat Design

Page load link

Press “ESC” key to close

main menu
  • Home
  • News
  • About Us
  • Contact
recent posts
  • Click Therapeutics secures $50M from Boehringer Ingelheim for schizophrenia digital therapy
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Digital & Data, Pharmaceuticals and therapeutics, Therapeutic Areas
  • Kainova Therapeutics doses first patient in Europe in phase 1/2 anti-CCR8 antibody trial
    Categories: Clinical & Regulatory, Therapeutic Areas
  • START appoints Salwan Al Mutar to lead clinical research in Dallas-Fort Worth
    Categories: Biotech & Pharma Business, Clinical & Regulatory, Therapeutic Areas
get connected
This website uses cookies and third party services. See our Cookie Policy and Privacy Policy pages for details. OK
Go to Top